SG11201801295WA - New crystal of piperazine compound - Google Patents

New crystal of piperazine compound

Info

Publication number
SG11201801295WA
SG11201801295WA SG11201801295WA SG11201801295WA SG11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA SG 11201801295W A SG11201801295W A SG 11201801295WA
Authority
SG
Singapore
Prior art keywords
new crystal
piperazine compound
piperazine
compound
crystal
Prior art date
Application number
SG11201801295WA
Other languages
English (en)
Inventor
Shinichi Aoki
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11201801295WA publication Critical patent/SG11201801295WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201801295WA 2015-09-17 2016-09-16 New crystal of piperazine compound SG11201801295WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015184022 2015-09-17
PCT/JP2016/077547 WO2017047791A1 (ja) 2015-09-17 2016-09-16 ピペラジン化合物の新規結晶

Publications (1)

Publication Number Publication Date
SG11201801295WA true SG11201801295WA (en) 2018-03-28

Family

ID=58289428

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201801295WA SG11201801295WA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound
SG10201912021VA SG10201912021VA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912021VA SG10201912021VA (en) 2015-09-17 2016-09-16 New crystal of piperazine compound

Country Status (22)

Country Link
US (1) US20180258069A1 (zh)
EP (1) EP3351542B1 (zh)
JP (1) JP6944372B2 (zh)
KR (1) KR102587705B1 (zh)
CN (1) CN108026068A (zh)
AU (1) AU2016324121B2 (zh)
BR (1) BR112018003448A2 (zh)
CA (1) CA2999009C (zh)
DK (1) DK3351542T3 (zh)
ES (1) ES2901157T3 (zh)
HK (1) HK1247921A1 (zh)
HU (1) HUE057813T2 (zh)
MA (1) MA42839A (zh)
MX (1) MX2018003320A (zh)
MY (1) MY193595A (zh)
PH (1) PH12018500399A1 (zh)
PL (1) PL3351542T3 (zh)
PT (1) PT3351542T (zh)
RU (1) RU2018113722A (zh)
SG (2) SG11201801295WA (zh)
TW (1) TWI707851B (zh)
WO (1) WO2017047791A1 (zh)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101218228A (zh) * 2005-05-23 2008-07-09 诺瓦提斯公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
GB0706793D0 (en) * 2007-04-05 2007-05-16 Evotec Ag Compounds
PL2407466T3 (pl) * 2009-03-09 2016-06-30 Taiho Pharmaceutical Co Ltd Związek piperazynowy zdolny do inhibitowania syntazy prostaglandyny d
AU2011208139B2 (en) * 2010-01-22 2014-10-23 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
JP6130701B2 (ja) * 2012-04-01 2017-05-17 エシャシ ファーマ リミテッドEshyasi Pharma Limited (2rs)−1−ジメチルアミノ−3−{2−[2−(3−メトキシフェニル)エチル]フェノキシ}プロパン−2−イルコハク酸水素塩酸塩の工業的製造方法
JP5999686B2 (ja) * 2012-04-05 2016-09-28 ロンシール工業株式会社 耐熱性ポリ乳酸系成形体、およびその製造方法
MX345435B (es) * 2012-09-19 2017-01-30 Taiho Pharmaceutical Co Ltd Composicion farmaceutica para la administracion oral con disolucion y/o absorcion mejorada.

Also Published As

Publication number Publication date
WO2017047791A9 (ja) 2017-05-18
KR20180051628A (ko) 2018-05-16
MX2018003320A (es) 2018-05-30
CA2999009A1 (en) 2017-03-23
PT3351542T (pt) 2021-12-21
KR102587705B1 (ko) 2023-10-12
TW201720818A (zh) 2017-06-16
HK1247921A1 (zh) 2018-10-05
WO2017047791A1 (ja) 2017-03-23
PH12018500399A1 (en) 2018-08-29
JPWO2017047791A1 (ja) 2018-07-05
EP3351542A1 (en) 2018-07-25
PL3351542T3 (pl) 2022-02-14
EP3351542A4 (en) 2019-04-24
RU2018113722A (ru) 2019-10-18
AU2016324121B2 (en) 2020-08-20
CN108026068A (zh) 2018-05-11
SG10201912021VA (en) 2020-02-27
HUE057813T2 (hu) 2022-06-28
CA2999009C (en) 2023-05-23
MY193595A (en) 2022-10-19
ES2901157T3 (es) 2022-03-21
US20180258069A1 (en) 2018-09-13
TWI707851B (zh) 2020-10-21
BR112018003448A2 (pt) 2018-09-25
DK3351542T3 (da) 2022-01-03
RU2018113722A3 (zh) 2019-12-23
MA42839A (fr) 2018-07-25
AU2016324121A1 (en) 2018-04-26
EP3351542B1 (en) 2021-11-17
JP6944372B2 (ja) 2021-10-06

Similar Documents

Publication Publication Date Title
HK1249905A1 (zh) 作為lsd1抑制劑的雜環化合物
IL255817B (en) Synthesis of heterocyclic compounds
IL250709A0 (en) Aminopyrimidines and their use to inhibit jak
SG11201706729SA (en) Derivatives of sobetirome
HK1245770A1 (zh) 尿嘧啶化合物的新型結晶
IL251780A0 (en) New compounds as nik inhibitors
SI3380554T1 (sl) Kristalne oblike per-kloro-gama-ciklodekstrinov
HK1244274A1 (zh) C21h22ci2n4o2的晶型
IL253479A0 (en) Crystalline forms of efinconazole
SI3159335T1 (sl) Nova heterociklična spojina
PL3247687T3 (pl) Zastosowanie masy wyrównującej
LT3424930T (lt) Junginio, turinčio jak slopinantį aktyvumą, kristalas
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
HK1247921A1 (zh) 哌嗪化合物的新晶體
HUP1500506A2 (en) Salts of palbociclib